Long-Term Oral Ciprofloxacin in the Treatment of Prosthetic Valve Endocarditis due to Pseudomonas Aeruginosa

References

• Dismukes W E, Karchmer A W, Buckley M J, Austen W G, Swartz M N. Prosthetic valve endocarditis: an analysis of 38 cases. Circulation 1973; 48: 365–377
   PubMed Web of Science ®Google Scholar
• Masur H, Johnson W D. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1980; 80: 31–37
   PubMed Web of Science ®Google Scholar
• Wilson W R, Jaumin P M, Danielson G K, Giuliani E R, Washington J A, Geraci J E. Prosthetic valve endocarditis. Ann Intern Med 1975; 82: 751–756
   PubMed Web of Science ®Google Scholar
• Wilson W R, Danielson G K, Giuliani E R, Geraci J E. Prosthetic valve endocarditis. Mayo Clin Proc 1982; 57: 155–161
   PubMed Web of Science ®Google Scholar
• Saffle J R, Gardner P, Schoenbaum S C, Wild W. Prosthetic valve endocarditis: the case for prompt valve replacement. J Thorac Cardiovasc Surg 1977; 73: 416–420
   PubMed Web of Science ®Google Scholar
• Reyes M P, Palutke W A, Wylin R F, Lerner A M. Pseudomonas endocarditis in the Detroit Medical center 1969–1972. Medicine (Baltimore) 1973; 52: 173–194
   PubMed Web of Science ®Google Scholar
• Strunk R W, Gratz J C, Maserati R, Scheld W M. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother 1985; 28: 428–432
   PubMedGoogle Scholar
• Bayer A S, Lindsay P, Yih J, Hirano L, Lee D, Blomquist I K. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply betalactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production. Antimicrob Agents Chemother 1986; 30: 428–431
   Google Scholar
• Bayer A S, Kim K S. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa. Chemotherapy 1986; 32: 364–373
   PubMedGoogle Scholar
• Bayer A S, Blomquist I K, Kim K S. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother 1986; 17: 641–649
   PubMedGoogle Scholar
• Thauvin C, Lecomte F, LeBoete I, Grise G, Lemeland J F. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa. Infection 1989; 17: 31–34
   PubMedGoogle Scholar
• Carpenter T C, Hackbarth C J, Chambers H F, Sande M A. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1986; 30: 382–384
   PubMedGoogle Scholar
• Kaatz G W, Barriere S L, Schaberg D R, Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1987; 31: 527–530
   PubMed Web of Science ®Google Scholar
• Fernandez-Guerrero M, Rouse M, Henry N, Wilson W. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1988; 32: 747–751
   PubMedGoogle Scholar
• Kaatz G W, Seo S M, Barriere S L, Albrecht L M, Rybak M J. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1989; 33: 1184–1187
   PubMedGoogle Scholar
• Rouse M S, Wilcox R M, Henry N K, Steckelberg J M, Wilson W R. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 1990; 34: 273–276
   PubMedGoogle Scholar
• Dworkin R J, Lee B L, Sande M A, Chambers H F. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989; 2: 1071–1073
   PubMed Web of Science ®Google Scholar
• Santiago M, Chocarro A, Chaves F, Sanchez-Zaballos I. Ciprofloxacin in the treatment of a case of endocarditis caused by Eikenella corrodens. Enferm Infecc Microbiol Clin 1990; 8: 188–189
   PubMedGoogle Scholar
• MacGowan A P, Reeves D S, Wright C, Glover S C. Tricuspid valve infective endocarditis and pulmonary sepsis due to Erysipelothrix rhusiopathiae successfully treated with high doses of ciprofloxacin but complicated by gynaecomastia. J Infect 1991; 22: 100–101
   PubMedGoogle Scholar
• Ena J, Amador C, Parras F, Bouza E. Ciprofloxacin as an effective antibacterial agent in serratia endocarditis. J Infect 1991; 22: 103–105
   PubMed Web of Science ®Google Scholar
• Levy P Y, Drancourt M, Etienne J, Auvergnat J C, Beytout J, Sainty J M, Goldstein F, Raoult D. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. Antimicrob Agents Chemother 1991; 35: 533–537
   PubMed Web of Science ®Google Scholar
• Daikos G L, Kathpalia S B, Lolans V T, Jackson G G, Fosslein E. Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis. Am J Med 1988; 84: 786–790
   PubMed Web of Science ®Google Scholar
• Kaatz G W, Barriere S L, Schaberg D R, Fekety R. The emergence of resistance to ciprofloxacin during therapy of experimental methicillin-suscptible Staphylococcus aureus endocarditis. J Antimicrob Chemother 1987; 20: 753–758
   PubMedGoogle Scholar
• Tebas P, MartinezRuiz R, Roman F, Mendaza P, RodriguezDiaz J C, Daza R, de Letona J M. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis 1991; 163: 204–205
   PubMedGoogle Scholar
• Bayer A S, Hirano L, Yih J. Development of betalactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother 1988; 32: 231–235
   PubMedGoogle Scholar